2020
DOI: 10.1111/dth.14374
View full text
|
Sign up to set email alerts
|
Share

Abstract: Biologics are frequently switched in psoriatic patients who do not respond adequately or experience adverse events under treatment. 1,2 While several studies have demonstrated efficacy and safety when switching between interleukin (IL)-17 inhibitors, 3-5 there is no such published data regarding IL-23 antagonists. We report a patient with psoriasis who was successfully treated with risankizumab after secondary nonresponse to ustekinumab and primary nonresponse to guselkumab and tildrakizumab.